Population Health

The Supreme Court’s temporary action on mifepristone telehealth access raises new questions about reproductive health policy, autonomy, and care access in the US.

There were about 70,000 Americans who died of drug overdoses in 2025, which continues a decline in drug overdoses that has lasted 3 years.

A cohort-based mortality study found major state-by-state life expectancy gaps, with Southern states lagging in longevity gains.

New real-world evidence presented at PQA 2026 exposes the blind spots in how medication adherence is measured, monitored, and misunderstood.

Here is a policy briefing for chief medical officers and managed care leaders on key pressure points about the Medicaid funding cuts.

Shara Bialo, MD, emphasizes the crucial role of school nurses in early detection of type 1 diabetes.

The Supreme Court temporarily restores mifepristone mail access, pausing a Fifth Circuit ruling that had blocked telehealth abortion pill prescriptions.

Chris Johnson, MBA, explains how retail-based pediatric clinics and smart tech can expand Medicaid access and streamline visits.

Marc P. Bonaca, MD, MPH, and Josephine Harrington, MD, discuss the clinical value of the uACR test and why it remains underutilized.

Experts examine what is working in production, where the guardrails are being tested, and why the most transformative chapter of AI in health care hasn’t started yet.

The future of specialty pharmacy is not automation alone, but technology designed to assist patients through personalized support.

The entire commercial logic of the pharmaceutical industry’s patient engagement model is built for a moment that no longer exists, according to Chris Moose.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

The DEA's 30th biannual collection event arrives April 25, 2026—here's what patients and clinicians need to know.

OUD diagnoses have declined, but use of medication to treat OUD has increased among Medicaid beneficiaries, highlighting policy gains and ongoing state-level disparities.

A new AHIP report outlines evidence-based strategies to cut chronic disease prevalence by 10% by 2035.

Public health must be grounded in empathy, cultural competence, psychological insight, and political awareness, emphasizes Perry N. Halkitis, PhD, MD, MPH.

Results of 2 programs show what it takes to move social determinants of health from research into clinical practice—and what’s still missing.

Food insecurity remains among children above SNAP limits, highlighting broad-based categorical eligibility gaps that exclude at-risk families just over eligibility thresholds.

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 through prevention and coordinated care.

Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives prioritize the complete screening continuum over initial test uptake.

The 2026 Regional Diabetes Summit is taking place from April 28 to 29, 2026, in Wilmington, Delaware.

The FDA is encouraging drug sponsors to pursue a new indication for testosterone replacement therapy.

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies.

John Barkett, MBA, discusses recent regulatory proposals to make massive health plan price files more usable.